drugset / Trial / NCT03162432

High Dose Interval Vitamin D Supplementation in Patients With IBD Receiving Remicade

NCT03162432

Phase 3 Unknown 50 enrolled Boston Children's Hospital
NaSingle-groupOpen-labelTreatment

Summary

The goal of this study will be to assess the safety and efficacy of high-dose interval Vitamin D3 therapy in children and young adults with Inflammatory Bowel Disease being treated with serial Remicade infusions.

Timeline

Start
2017-08-01
Primary completion
2023-12-01
Completion
2023-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified 50000 iu Oral
Subject Cholecalciferol Other / unclassified 100000 iu Oral